Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Interim Management Statement

20 Oct 2011 07:00

RNS Number : 5036Q
Xaar PLC
20 October 2011
 



  

FOR IMMEDIATE RELEASE

20 October 2011

 

 

 

Xaar plc

 

 

INTERIM MANAGEMENT STATEMENT AND ANALYST DAY

 

 

Xaar plc ("Xaar" or "the Group"), the inkjet printing technology group headquartered in Cambridge, is providing an Interim Management Statement covering trading from 1 July 2011.

 

Revenue and profit for the third quarter of the year were ahead of the Board's expectations. The Board anticipate that this level of trading will continue during Q4, leading to a strong performance for the full year 2011.

 

Sales of Platform 3 ("P3") products in Q3 grew ahead of expectations through the successful completion of the early stages of the capacity expansion programme. This has relieved the short term supply constraint, slightly earlier than anticipated, with the result that P3 revenues are now demand driven. The remaining critical stages of the programme are on track for completion through the fourth quarter of 2011 and the first half of 2012.

 

Sales of Platform 1 ("P1") products have performed in line with expectations, with revenue for Q3 2011 slightly lower than Q2 2011, however forward visibility remains limited.

 

Royalty income for the year to date has increased compared to the same period last year, reflecting, in part, some market share loss to licensees in markets serviced by P1 products.

 

The Group's balance sheet remains strong with net cash at 30 September 2011 of £16.8 million (30 June 2011 - £20.6m, 31 December 2010: £22.0 million). The reduction in net cash reflects planned expenditures related to the capacity expansion.

 

To date, the global economic environment has not impacted Xaar's trading. However, the Board remain cautious and continue to monitor sales channels closely.

 

Today, Xaar is hosting an open day for analysts at its Huntingdon manufacturing facility. The purpose is to update analysts on progress with the capacity expansion and to discuss the markets for its P3 products. No new information will be presented.

 

END

 

CONTACTS

 

Xaar plc:

01223-423663

Ian Dinwoodie, Chief Executive

www.xaar.com

Alex Bevis, Finance Director

Singer Capital Markets Limited:

020-3205-7500

Shaun Dobson

Bankside Consultants:

Simon Bloomfield

020-7367-8888 / 07771-758517

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBLBDGGBBBGBC
Date   Source Headline
3rd Feb 20254:15 pmRNSTotal Voting Rights
22nd Jan 202512:30 pmRNSBlock listing Interim Review
21st Jan 20253:00 pmRNSHolding(s) in Company
15th Jan 20257:00 amRNSTrading update & notification of full year results
15th Jan 20257:00 amRNSAppointment of Chief Financial Officer
11th Dec 202410:30 amRNS2024 Full Year Trading Update
4th Dec 202410:45 amRNSUpdate statement on 2024 AGM voting results
3rd Dec 202410:50 amRNSTotal Voting Rights
20th Nov 20247:00 amRNSBoard changes
1st Nov 202412:00 pmRNSTotal Voting Rights
1st Oct 202411:30 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
2nd Sep 20241:45 pmRNSTotal Voting Rights
2nd Aug 20242:30 pmRNSHolding(s) in Company
1st Aug 202411:15 amRNSTotal Voting Rights
30th Jul 20247:00 amRNSNOTICE OF RESULTS AND UPDATE ON TRADING
3rd Jul 202411:45 amRNSBlock listing Interim Review
2nd Jul 20242:00 pmRNSTotal Voting Rights
28th Jun 202410:00 amRNSDirector Declaration
3rd Jun 20242:45 pmRNSTotal Voting Rights
30th May 202412:00 pmRNSBoard changes
29th May 20241:45 pmRNSResult of AGM
29th May 20249:30 amRNSHolding(s) in Company
21st May 20249:30 amRNSDirector/PDMR Shareholding
20th May 20244:30 pmRNSDirector/PDMR Shareholding
13th May 20249:42 amRNSHolding(s) in Company
1st May 20244:15 pmRNSTotal Voting Rights
30th Apr 20244:30 pmRNSDirector/PDMR Shareholding
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.